0613 GMT - Novo Nordisk's full-year guidance will be the focus of the company's upcoming earnings report, Citi analysts write. Key will be if, and by how much, the company raises its outlook given strong prescription trends of the Wegovy pill and injection, Citi adds. The bank thinks a guidance raise is expected by the market and priced in. Citi forecasts second-quarter adjusted operating income of 27.2 billion Danish kroner, down 9% at constant currencies, with sales 1% lower at 72.7 billion kroner. It expects continued price pressure in both the obesity and diabetes franchises, partially offset by a continued strong performance of the Wegovy weight-loss pill. It raises its target price on the stock to 330 kroner from 290 kroner and keeps its neutral rating. Shares closed at 329.90 kroner. (dominic.chopping@wsj.com)

(END) Dow Jones Newswires

July 20, 2026 02:14 ET (06:14 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.